BIIB
Biogen Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website biogen.com
- Employees(FY) 8725
- ISIN US09062X1037
Performance
-1.28%
1W
-10.82%
1M
-21.81%
3M
-33.35%
6M
-39.03%
YTD
-32.54%
1Y
Profile
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Technical Analysis of BIIB 2024-12-06
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-12-05 19:30
- 2024-12-05 09:13
- 2024-12-05 04:40
- 2024-12-04 18:31
- 2024-12-04 05:31
- 2024-12-02 07:44
Analyst Report: Biogen Inc.(Morningstar Research)
- 2024-11-29 13:12
- 2024-11-29 09:40
- 2024-11-28 06:08
- 2024-11-27 19:31
- 2024-11-27 17:08
- 2024-11-27 09:15
- 2024-11-27 06:31
- 2024-11-26 14:23
Eli Lilly Pops After Biden Proposes Medicare Cover Obesity Drugs. Is Lilly Stock A Buy?(Investor's Business Daily)
- 2024-11-22 06:45
- 2024-11-21 18:45
- 2024-11-20 13:32
- 2024-11-20 10:13
- 2024-11-19 19:06
- 2024-11-19 05:14
- 2024-11-19 01:00
- 2024-11-18 13:18
- 2024-11-18 12:00
- 2024-11-18 11:30
Needham downgrades Biogen on slow growth of Alzheimer's drug(Investing.com)
- 2024-11-18 07:39
Needham Downgrades Biogen to Hold From Buy(MT Newswires)
- 2024-11-18 07:00
- 2024-11-18 06:02
Needham Downgrades Biogen to Hold From Buy(MT Newswires)
- 2024-11-18 04:25
Is Biogen Inc. (BIIB) A Cheap NASDAQ Stock To Invest In Now?(Insider Monkey)
- 2024-11-18 00:40
Analyst Report: Biogen Inc.(Morningstar Research)
- 2024-11-17 18:00
Page 1 of 10
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.